Ed, when you, when you're brought in, uh, in whatever capacity, let's say as an expert witness, what are the first questions that you ask?

So I think particularly recently, um, there have been new theories advanced by the Qui Tam Bar.

Uh, I'm involved in two cases now, um, that are fairly novel theories.

So the first thing I do a- as an expert, you know, when we do our due diligence, uh, to be able to take the case.

So I'll typically do a case assessment upfront, and it involves if it's, if it's a pharma pricing case, we'll run our own analytics with counsel, and we'll look at exposure analysis, we'll look at trending analysis, we'll look at along the decision tree.

When it's something sort of less, um, obvious than a pricing decision but still related to price, because in pharma most things ultimately are related to price, you know, I'll have to examine a theory.

So for example, one of the new theories that's being advanced, and there's actually a split in the circuits, is there is a case, um, and it's public knowledge, Silvershire versus Janssen versus a number of other defendants.

I'm a compli- Y-you see the compliance officers in, in, in the cases that, that you're involved in, and what advice do you have compli- for compliance officers to stay out of trouble with some of these cases, the Qui tam cases, uh, and the, uh, the Qui tam cases?